AMGN vs CERS · P/E 24, rev $36.75B vs rev $201.3M
Amgen Inc (AMGN) versus Cerus Corporation (CERS) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Cerus Corporation (CERS) is a medical devices company listed on US.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported CERS revenue for 2024-12-31 was $201.3M. Net income was -$21.0M. Revenue was up 7.8% from 2023-12-31 to 2024-12-31. CERS currently screens at market cap $294.4M.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. CERS currently screens at market cap $294.4M.
Not investment advice. Open the AMGN and CERS stock pages for the full models.
Not investment advice.